ARTICLE | Financial News
Vical down on clinical trial news
April 20, 2001 7:00 AM UTC
VICL was off $3.65 (22%) to $13 on Friday. On Thursday after market close, the company discontinued its Phase II trial of Leuvectin, a lipid formulation of DNA encoding interleukin-2 (IL-2), in patien...